| 000 | 01612 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515074915.0 | ||
| 264 | 0 | _c20071227 | |
| 008 | 200712s 0 0 eng d | ||
| 022 | _a2046-4924 | ||
| 024 | 7 |
_a10.3310/hta11290 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aColbourn, T | |
| 245 | 0 | 0 |
_aPrenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses. _h[electronic resource] |
| 260 |
_bHealth technology assessment (Winchester, England) _cAug 2007 |
||
| 300 |
_a1-226, iii p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBacterial Infections _xdrug therapy |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 |
_aDelivery, Obstetric _xstatistics & numerical data |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant Mortality |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 |
_aPrenatal Diagnosis _xeconomics |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aStillbirth |
| 650 | 0 | 4 |
_aStreptococcal Infections _xdrug therapy |
| 650 | 0 | 4 | _aStreptococcus agalactiae |
| 700 | 1 | _aAsseburg, C | |
| 700 | 1 | _aBojke, L | |
| 700 | 1 | _aPhilips, Z | |
| 700 | 1 | _aClaxton, K | |
| 700 | 1 | _aAdes, A E | |
| 700 | 1 | _aGilbert, R E | |
| 773 | 0 |
_tHealth technology assessment (Winchester, England) _gvol. 11 _gno. 29 _gp. 1-226, iii |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3310/hta11290 _zAvailable from publisher's website |
| 999 |
_c17185541 _d17185541 |
||